- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: arbekacin sulfate | habekacin | ME1100 | NPC-14
arbekacin is an approved drug
Compound class: Synthetic organic
|No information available.|
|Summary of Clinical Use|
|Arbekacin is a potent aminoglycoside antibiotic already approved in some countries to treat multidrug-resistant bacteria. An inhalation solution of arbekacin (ME1100) is being developed for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia.
Several aminoglycoside antibiotics, including arbekacin, have been reported to have the ability to promote mRNA translation even in the presence of premature termination codons (PTCs) in mutated genes. In the absence of pharmaceutical intervention, the ribosomal translation process produces truncated, often non-functional protein products. However, in the presence of such compounds the ribosomes 'readthrough' the PTCs, producing increased amounts of full-length, functional protein. This developing pharmaceutical intervention has been termed 'readthrough strategy' and has led to a repurposing effort, with the compound now being evaluated in clinical trial as a treatment for Duchenne muscular dystrophy (DMD), in patients where the inherited genetic mutation causes production of truncated, non-functional dystrophin. Dystrophin is a protein critical for muscle function. For more information regarding current clinical trials testing arbekacin, visit www.clinicaltrials.gov.
|Mechanism Of Action and Pharmacodynamic Effects|
|Arbekacin promotes ribosomal readthrough of PTCs, thereby increasing transcription of full-length, functional proteins.|
|Clinical Trial ID||Title||Type||Source||Comment||References|
|NCT02459158||A Study to Assess the Pharmacokinetic Profile, the Safety, and the Tolerability of ME1100 Inhalation Solution in Patients With Mechanically Ventilated Bacterial Pneumonia||Phase 1 Interventional||Meiji Seika Pharma Co., Ltd.||2|
|NCT01918384||Phase II Study of NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dystrophy||Phase 2 Interventional||Kobe University|